Sialic acid metabolism orchestrates transcellular connectivity and signaling in glioblastoma.

Ugne Kuliesiute, Kevin Joseph, Jakob Straehle, Vidhya Madapusi Ravi, Jan Kueckelhaus, Jasim Kada Benotmane, Junyi Zhang, Andreas Vlachos, Juergen Beck, Oliver Schnell, Urte Neniskyte, Dieter Henrik Heiland

Journal: Neuro-oncology 2023;25(11):1963-1975

PMID: 37288604

Abstract

BACKGROUND

In glioblastoma (GBM), the effects of altered glycocalyx are largely unexplored. The terminal moiety of cell coating glycans, sialic acid, is of paramount importance for cell-cell contacts. However, sialic acid turnover in gliomas and its impact on tumor networks remain unknown.

METHODS

We streamlined an experimental setup using organotypic human brain slice cultures as a framework for exploring brain glycobiology, including metabolic labeling of sialic acid moieties and quantification of glycocalyx changes. By live, 2-photon and high-resolution microscopy we have examined morphological and functional effects of altered sialic acid metabolism in GBM. By calcium imaging we investigated the effects of the altered glycocalyx on a functional level of GBM networks.

RESULTS

The visualization and quantitative analysis of newly synthesized sialic acids revealed a high rate of de novo sialylation in GBM cells. Sialyltrasferases and sialidases were highly expressed in GBM, indicating that significant turnover of sialic acids is involved in GBM pathology. Inhibition of either sialic acid biosynthesis or desialylation affected the pattern of tumor growth and lead to the alterations in the connectivity of glioblastoma cells network.

CONCLUSIONS

Our results indicate that sialic acid is essential for the establishment of GBM tumor and its cellular network. They highlight the importance of sialic acid for glioblastoma pathology and suggest that dynamics of sialylation have the potential to be targeted therapeutically.

© The Author(s) 2023. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: [email protected].

Address: Microenvironment and Immunology Research Laboratory, Medical Center, University of Freiburg, Freiburg, Germany.; Department of Neurosurgery, Medical Center, University of Freiburg, Freiburg, Germany.; Faculty of Medicine, Freiburg University, Freiburg, Germany.; Institute of Biosciences, Life Sciences Center, Vilnius University, Vilnius, Lithuania.; VU LSC-EMBL Partnership for Genome Editing Technologies, Life Sciences Center, Vilnius University, Vilnius, Lithuania.; Department of Neuroanatomy, Institute of Anatomy and Cell Biology, Faculty of Medicine, University of Freiburg, Freiburg, Germany.; Center Brain Links Brain Tools, University of Freiburg, Freiburg, Germany.; Center for Basics in Neuromodulation, Faculty of Medicine, University of Freiburg, Freiburg, Germany.; Department of Neurological Surgery, Lou and Jean Malnati Brain Tumor Institute, Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.; Comprehensive Cancer Center Freiburg (CCCF), Faculty of Medicine and Medical Center-University of Freiburg, Freiburg, Germany.; German Cancer Consortium (DKTK), partner siteFreiburg.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.